Guardant Health today shared results from a 778-sample, blinded case-control study demonstrating that its methylation-based Shield™ Multi-Cancer Detection (MCD) blood test achieves:
- 98.5% specificity
- 60% overall sensitivity across ten cancer types
- 74% sensitivity for the six most aggressive cancers (esophageal-gastric, hepatocellular, lung, ovarian, pancreatic)
- 89% accuracy in predicting cancer signal of origin